News Hengrui to file obesity shot in China after phase 3 win An obesity therapy developed by Hengrui Pharma and Kailera is being prepared for its first regulatory submission, in China.
News MSD licenses Lp(a) heart drug from Hengrui in $2bn deal MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200m upfront.
News Merck signs €1.4bn cancer alliance with China’s Hengrui Germany’s Merck KGaA has reached a deal with Chinese pharma company Jiangsu Hengrui that covers a pair of cancer drugs, including a ‘next-generation’ PARP inhibitor and an
